好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Relationships between DMD mutations and neurodevelopment in dystrophinopathy
Neuromuscular and Clinical Neurophysiology (EMG)
P5 - Poster Session 5 (5:30 PM-6:30 PM)
12-002

We performed a prospective, cross-sectional analysis of neurodevelopmental concerns and psychosocial adjustment in relation to DMD mutations in young steroid-naïve boys with dystrophinopathy.

We evaluated 196 steroid-naïve boys with dystrophinopathy who were enrolled in the Finding the Optimal Regimen for Duchenne Muscular Dystrophy (FOR-DMD) trial. The neurodevelopmental concerns and psychosocial adjustment challenges were analyzed in relation to DMD mutation. Neurodevelopmental concerns in four domains (speech, learning and attentional difficulties, and autism spectrum disorder (ASD)) and Personal Adjustment and Role Skills Scale (PARS-III) to assess psychosocial adjustment were evaluated.

Study measures and Study-related questionnaires

Parents or legal guardians completed study-related review-of-systems during the first study visit. Specifically, the subject’s medical history included age (in months) at which the subject began to speak in full sentences, speech delay (yes, no, unknown) and learning difficulties (yes, no or unknown). A parent or legal guardian completed the following questionnaires during the study subject’s screening visit: IOWA Conners scale for ADHD, and PARS-III questionnaire for psychosocial adjustment.


We observed that 39% of boys were reported to have speech delay with a mean age of speaking of 28 months (range 7 to 66 months). Learning difficulties were reported in 28% of subjects. Inattentive-overactive (IO) and oppositional-defiant (OD) behavior was reported in 8% and 5% of subjects, respectively. Psychosocial adjustment challenges were reported in 4% of subjects. Speech delay, learning difficulties and OD behavior were more common in boys with mutations downstream of DMD exon 45. Boys of DMD carrier mothers did not have longer speech delay or more learning difficulties. 

Our data support evidence for a relationship between neurodevelopmental concerns and DMD mutation. A longitudinal assessment of developmental trajectory is necessary to evaluate how specific DMD mutations affect brain function. 
Authors/Disclosures
Mathula Thangarajh, MD, PhD, FAAN
PRESENTER
Dr. Thangarajh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sarepta. Dr. Thangarajh has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for NS Pharma.
No disclosure on file
Michael McDermott No disclosure on file
William Martens (University of Rochester) William Martens has nothing to disclose.
Kimberly A. Hart, MA (University of Rochester Medical Center, Department of Neurology) No disclosure on file
Robert C. Griggs, MD, FAAN (University of Rochester Department of Neurology) Dr. Griggs has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Strongbridge Pharmaceuticals. Dr. Griggs has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Idera Pharmaceuticals. Dr. Griggs has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Solid Biopharma. Dr. Griggs has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Santhera Pharmaceuticals. Dr. Griggs has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. Dr. Griggs has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Lippincott. The institution of Dr. Griggs has received research support from PTC Pharmaceuticals. The institution of Dr. Griggs has received research support from Sarepta Pharmaceuticals. The institution of Dr. Griggs has received research support from National Institutes of Health. The institution of Dr. Griggs has received research support from Santhere Pharmaceuticals. Dr. Griggs has received personal compensation in the range of $500-$4,999 for serving as a Study section member with National Institutes of Health. Dr. Griggs has a non-compensated relationship as a Board of Directors;Chair Research Advisory Committee with American Brain Foundation that is relevant to AAN interests or activities.